Skip to main content

Table 1 Baseline characteristics of the included studies

From: The prevalence of hepatitis C and hepatitis B in lesbian, gay, bisexual and transgender populations: a systematic review and meta-analysis

Authors (year)

Type of study (country)

Study population (type)

Age (mean)

Sample size (N)

HBV prevalence

N (%)

HCV prevalence

N (%)

Number (type of laboratory test)

Johnston et al. [16]

Cross-sectional (Dominican Republic)

LGBT

≥ 15

1388

28 (2.05%)

53 (3.85%)

HBV: HBsAg BIO-CARD HCV: Bioblot HCV

Gutierrez et al. [17]

Cross-sectional (Spain)

LGBT

18–41

762

27 (3.5%)

6 (0.8%)

HBV: microparticle Enzyme Immunoassay

HCV: ELISA, line immunoassay

Carobene et al. [2]

Cross-sectional (Argentina)

TGs (Both)

29

273

106 (40%)

12 (4.5%)

ELISA, particle Agglutination

Luzzati et al. [18]

Retrospective (Italy)

TGs (Both)

33.5 ± 7.7

243 (MTF: 218

FTM: 25)

MTF: 10 (4.6%)

FTM: 2 (4%)

MTF: 8 (3.5%)

FTM: 2 (8%)

HBV: immunoassays Enzygnost, Chemiluminescent microparticle Immunoassay, CMIA

HCV: immunoassay Ortho HCV 3.0 Elisa Test System, immunoblotting

Chiron Riba HCV 3.0 SIA

Ahsan et al. [19]

Retrospective (Pakistan)

TGs (both)

All ages

877

NR

128 (14.6%)

HCV: RAPID ICT test, ELISA

Brito et al. [20]

Cross-sectional (Dominican Republic)

MTF

≥ 18

100

4 (4%)

1 (1%)

HBV: hepatitis B surface antigen (HBsAg II, COBAS, Roche Diagnostics)

HCV: hepatitis C antibody

(anti-HCV II, COBAS, Roche Diagnostics)

Krieger et al. [21]

Retrospective (USA)

TGs (Both)

35.5–41.3

1005

48 (4.8%)

NR

HBV serology

(surface antigen and antibody)

Facente et al. [22]

Cross-sectional (USA)

MTF

> 30

951

NR

236 (24.8%)

HCV: ELISA

Adeyemi et al. [23]

Cross-sectional (Nigeria)

MTF

25

717

69 (10%)

NR

HBV serology (surface antigen and antibody)

Hadikusumo et al. [24]

Cross-sectional (Indonesia)

TGs (Both)

19–60

107

10 (9.3%)

7 (6.5%)

HBV: reverse passive hemagglutination assay, PCR

HCV: reverse particle hemagglutination method, PCR